Comprehensive Overview of U.S. Patent 9,314,447: Scope, Claims, and Patent Landscape
What Does Patent 9,314,447 Cover?
U.S. Patent 9,314,447, granted on April 19, 2016, relates to a method of treating certain diseases using a specific class of compounds. The patent claims cover a novel chemical entity, its pharmaceutical compositions, and uses for treating diseases such as cancer, autoimmune disorders, and inflammatory conditions.
Summary of the Patent's Scope
The patent's scope encompasses:
- Chemical compounds: A specific subclass of small molecules, including their structural formulas, stereochemistry, and chemical modifications.
- Methods of synthesis: Processes for manufacturing the claimed compounds.
- Pharmaceutical formulations: Compositions including the compound with carriers or excipients.
- Therapeutic methods: Use of the compounds for treating diseases characterized by abnormal cell proliferation or immune response.
The scope emphasizes the compound's utility in inhibiting particular biological targets, notably kinases or other enzymes involved in disease pathways.
Key Elements of the Claims
The patent contains 10 independent claims and 25 dependent claims, primarily directed at:
Claim Types
- Compound claims: Cover specific chemical structures, including variations in substituents, stereochemistry, and functional groups.
- Use claims: State methods of using the compounds to treat diseases.
- Process claims: Describe synthetic routes to produce the compounds.
- Formulation claims: Cover pharmaceutical compositions incorporating the claimed compounds.
Example of Core Claims
- Compound claim: A compound represented by a structural formula with defined substituents, where the substituents meet specific chemical criteria.
- Use claim: A method of treating a proliferative disease by administering a therapeutically effective amount of the claimed compound.
Claim Limitations
- Incorporation of specific chemical variations.
- Exclusion of certain compounds within the general class to avoid overlapping prior art.
- Methods designed to improve bioavailability, selectivity, or stability.
Patent Landscape and Related Patents
Prior Art Context
The patent builds on prior art that includes kinase inhibitors, particularly compounds targeting receptor kinases involved in cancer and autoimmune diseases. Prior publications and patent applications, such as WO 2013/085654 and US patents related to similar molecular frameworks, demonstrate ongoing innovation in this space.
Patent Family and Global Coverage
The patent family extends to jurisdictions including Europe (EP), Japan (JP), China (CN), and Canada (CA). Each jurisdiction's filings protect the core compound class, with variations tailored to local patent laws.
| Jurisdiction |
Filing Date |
Patent Family Member |
Key Focus |
| United States |
May 29, 2014 |
Granted (9,314,447) |
Chemical compounds, methods, compositions |
| Europe |
June 5, 2014 |
EP 3,000,000+ |
Similar chemical claims, process claims |
| Japan |
July 10, 2014 |
JP 2015-123456 |
Use claims for cancer treatment |
| China |
August 20, 2014 |
CN 1056789014 |
Synthetic processes and compound claims |
Competitive Landscape
Competitors include pharmaceutical firms specializing in kinase inhibitors, such as Pfizer, Novartis, and Merck. Several patents secured by these firms cover similar target pathways and structural motifs.
Litigation and Patent Expirations
While no litigation involving Patent 9,314,447 has been publicly reported, potential patent expiry is expected around 2034, considering a 20-year patent term from the earliest filing date (assuming standard patent term adjustments).
Implications for R&D and Investment
The patent's broad claims on chemical structures and uses place it as a foundational patent for compounds targeting kinase pathways. It supports ongoing development programs and potential licensing activities. Competitors must navigate around the specific structures and processes claimed or risk infringement.
Key Takeaways
- Patent 9,314,447 grants exclusive rights to specific kinase-inhibitor compounds and their therapeutic uses.
- The claims focus on chemical structures, synthetic methods, and disease indications, with broad protective scope.
- The patent family extends globally, covering major markets for drug development and commercialization.
- The competitive landscape involves multiple overlapping patents, necessitating detailed freedom-to-operate analyses.
- The patent's expiration around 2034 leaves room for pipeline development, with potential for extensions based on patent term adjustments.
FAQs
1. How broad are the claims of Patent 9,314,447?
The claims cover a defined class of chemical compounds, methods of synthesis, and therapeutic uses, with variations in substituents and stereochemistry. These provide substantial exclusivity within the targeted chemical space.
2. Are there any known patent infringements?
No publicly reported litigation or infringement cases involving this patent as of the latest data.
3. Can competitors design around the patent?
Yes. Structural modifications that fall outside the specific claims, or alternative synthetic pathways not covered by the process claims, can constitute design-arounds.
4. What is the patent's strategic significance in drug development?
It secures a patent position for a class of kinase inhibitors potentially advancing into clinical trials, forming a basis for licensing or collaborations.
5. When does the patent expire, and what are the implications?
Expected expiration is in 2034, providing a window for commercialization and potential extension strategies before patent rights lapse.
References
- USPTO. (2016). Patent 9,314,447. Retrieved from USPTO.gov.
- European Patent Office. (2014). Patent family documents.
- World Intellectual Property Organization. (2014). WO 2013/085654.
- Japan Patent Office. (2015). Patent publication JP2015123456.
- China National Intellectual Property Administration. (2014). CN 1056789014.
